Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The global cancer vaccine market size was valued at USD 8.94 Billion in 2025 , driven by increasing initiatives from pharmaceutical giants to develop the most effective cancer vaccine. The market size is projected to grow at a CAGR of 11.80% during the forecast period 2026-2035 to reach a value of USD 27.27 Billion by 2035 .
Tasa de crecimiento anual compuesta
11.8%
Valorar USD Billion
2026-2035
The market is driven by researchers who dedicate their efforts to discovering innovative combinations and developing effective vaccines against various types of cancer. Demand in the cancer vaccine market is fueled by the increasing prevalence of cancer cases globally. In 2023, approximately 20 million new cancer cases were diagnosed, and nearly 10 million deaths were recorded worldwide. The cancer burden is projected to increase by approximately 60% over the next two decades, placing greater pressure on healthcare systems, individuals, and communities. The global burden is projected to reach approximately 30 million new cancer cases by 2040, with a high incidence in low- and middle-income countries. As a result, industry leaders are joining forces to collaborate, conduct clinical trials, and develop cancer vaccine candidates.
Increased adoption of innovative alternatives to provide precise treatment
In August 2023, the National Health Service (NHS) in England, the UK's public healthcare system, launched a cancer vaccine that can reduce treatment time for some patients by three-quarters. Atezolizumab (Tencentriq®), an immunotherapy drug, has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and is administered intravenously in about 7 minutes, a significant reduction from conventional treatment time.
The launch of this injection is good news for both patients and healthcare providers, as it allows oncologists to administer treatment more quickly and conveniently. This approach is likely to contribute to greater patient awareness and deliver significant growth in the cancer vaccine market over the forecast period. The NHS's rapid adoption of this innovation demonstrates its commitment to improving the efficiency of healthcare services.
Strategic collaborations between market players
In October 2023, BioNTech SE announced that Autogene cevumeran (also known as BNT122, RO7198457), a targeted therapeutic vaccine candidate for the treatment of pancreatic ductal adenocarcinoma (PDAC), had advanced to Phase 2 trials after showing promising results in Phase 1 clinical trials. In Phase 2, the efficacy of cevumeran will be evaluated in 260 patients, in combination with the anti-PD-L1 immune checkpoint inhibitor atezolizumab and chemotherapy. The combination treatment will be compared to the current standard of care (mFOLFIRINOX).
The candidate is being jointly developed by BioNTech and Genentech (a member of the Roche Group) and is based on the mRNA-based neoantigen-specific individualized immunotherapy (iNeST) platform. This alliance of leading companies to design enhanced and personalized solutions is a significant market trend that is expected to positively influence the market share of cancer vaccines during the forecast period.
El informe y previsión sobre el mercado de las vacunas contra el cáncer 2026-2035 ofrece un análisis detallado del mercado basado en los siguientes segmentos:
Desglose del mercado por tecnología
Desglose del mercado por tipo de vacuna
Desglose del mercado por aplicación
Desglose del mercado por región
From a geographic perspective, North America is expected to dominate the market during the forecast period. In 2023, the region recorded 609,280 cancer-related deaths. According to the National Cancer Institute, an estimated 2 million people in the United States will be diagnosed with cancer in 2024. By 2040, the number of people diagnosed with cancer will increase by 57%, affecting approximately 6.23 million individuals. As a result, significant emphasis has been placed on developing effective solutions for preventing cancer-related deaths.
Europe holds a significant market share in cancer vaccines, thanks to the presence of leading academic and research institutions, coupled with substantial funding for research activities. Increasing collaboration between healthcare companies and academic institutions is expected to drive significant market growth in the region. The Asia-Pacific region is also experiencing growth, which can be attributed to the increasing integration of modern technologies into the medical ecosystem. Growing efforts by emerging market governments to improve infrastructure are another notable market trend in the region.
In February 2023, Moderna, Inc. and Merck announced that the FDA had granted Breakthrough Therapy designation to mRNA-4157/V940 in combination with pembrolizumab (Keytruda) for the adjuvant treatment of patients with high-risk melanoma following complete resection. The designation was based on positive results from the Phase 2b KEYNOTE-942 trial (NCT03897881). mRNA-4157/V940 is a novel, investigational, personalized cancer vaccine based on messenger ribonucleic acid (mRNA), composed of a single synthetic mRNA that encodes up to 34 neoantigens. It works by eliciting an innate immune response and generating specific T-cell responses.
Key features of the cancer vaccines market report include patent analysis, grant analysis, clinical trial analysis, funding and investment analysis, partnerships, and collaboration analysis of key players. The leading companies in the market are as follows:
Please note that this is only a partial list of companies and the full list is included in the report.
*Si bien nos esforzamos por brindarle siempre información actual y precisa, los números representados en el sitio web son indicativos y pueden diferir de los números reales en el informe principal. En Expert Market Research, nuestro objetivo es brindarle las últimas ideas y tendencias en el mercado. Utilizando nuestros análisis y pronósticos, las partes interesadas pueden comprender la dinámica del mercado, navegar los desafíos y capitalizar las oportunidades para tomar decisiones estratégicas basadas en datos.*
El mercado alcanzó un valor aproximado de USD 8.94 Billion en 2025, impulsado por el aumento de la incidencia del cáncer en todo el mundo.
Se prevé que el mercado crezca a una tasa compuesta anual (CAGR) del 11.80 % durante el periodo de previsión de 2026-2035 y que alcance un valor de mercado de USD 27.27 Billion en 2035.
La creciente concienciación de la población sobre las vacunas personalizadas contra el cáncer, el aumento de las actividades de investigación sobre la incidencia, los ensayos clínicos, el lanzamiento de vacunas y las aprobaciones de la FDA están impulsando la demanda del mercado.
Las empresas farmacéuticas están tomando numerosas iniciativas para colaborar y desarrollar las vacunas contra el cáncer más eficaces, lo que constituye una importante tendencia del mercado. En octubre de 2023, BioNTech SE reveló que Autogene cevumeran (también conocido como BNT122, RO7198457), una vacuna terapéutica individualizada contra el cáncer candidata para el tratamiento del adenocarcinoma ductal pancreático (PDAC) desarrollada por una asociación entre BioNTech y Genentech, pasó a la fase 2 de los ensayos tras mostrar resultados prometedores en los ensayos clínicos de fase 1.
Las principales regiones del mercado son América del Norte, Europa, Asia-Pacífico, América Latina, Oriente Medio y África. América del Norte lidera actualmente el mercado mundial.
Las tecnologías incluidas son vacunas recombinantes contra el cáncer, vacunas contra el cáncer de células completas, vacunas contra el cáncer con vectores virales y DNA, y otras tecnologías.
Los tipos comunes de vacunas contra el cáncer incluyen vacunas preventivas y vacunas terapéuticas.
Las áreas de aplicación comunes incluyen el cáncer de próstata y el cáncer de cuello uterino, entre otros.
Los principales actores que participan en el mercado son Merck & Co., Inc., GlaxoSmithKline plc., Dendreon Pharmaceuticals LLC, Bristol Myers Squibb Company, AstraZeneca, F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi, Pfizer Inc., Gilead Sciences, Inc., Inovio Pharmaceuticals, Bavarian Nordic, CureVac SE, Takeda Pharmaceutical Company Limited y Cascadian Therapeutics.
Explore nuestros aspectos clave del informe y obtenga una visión general concisa de los hallazgos clave, las tendencias y las ideas procesables que capacitarán sus decisiones estratégicas.
| REPORT CHARACTERISTICS | DETAILS |
| Base year | 2025 |
| Historical period | 2019-2025 |
| Forecast period | 2026-2035 |
| Scope of the report |
Historical trends and forecasts, driving factors and limitations of the sector, historical analysis and market forecasts by segment:
|
| Breakdown by technology |
|
| Breakdown by vaccine type |
|
| Breakdown by application |
|
| Breakdown by region |
|
| Market dynamics |
|
| Competitive landscape |
|
| Companies included |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
Cómo ordenar
Seleccione Tipo de licencia
Elija la licencia correcta para sus necesidades y derechos de acceso.
Haga clic en "Comprar ahora"
Agregue el informe a su carrito con un clic y proceda a registrarse.
Seleccionar modo de pago
Elija una opción de pago para un pago seguro. Serás redirigido en consecuencia.
Soluciones estratégicas para la toma de decisiones informadas
Obtenga información para mantenerse a la vanguardia y aprovechar las oportunidades.
Obtenga ideas y tendencias para una ventaja competitiva.
Rastree los precios con informes de tendencias detallados.
Analice los datos comerciales para obtener información sobre la cadena de suministro.
Informes de costos de apalancamiento para ahorros inteligentes
Mejorar la cadena de suministro con asociaciones.
Conectarse para más información
Nuestro equipo experto de analistas ofrecerá soporte total y resolverá cualquier consulta con respecto al informe, antes y después de la compra.
Nuestro equipo experto de analistas ofrecerá soporte total y resolverá cualquier consulta con respecto al informe, antes y después de la compra.
Empleamos métodos de investigación meticulosos, combinando análisis avanzados y ideas de expertos para ofrecer inteligencia de la industria precisa y procesable, manteniéndose por delante de los competidores.
Nuestros analistas calificados ofrecen una ventaja competitiva incomparable con ideas detalladas sobre los mercados actuales y emergentes, asegurando su ventaja estratégica.
Ofrecemos una presentación en profundidad pero simplificada de los conocimientos y análisis de la industria para cumplir con sus requisitos específicos de manera efectiva.
Estamos aquí para ayudar a responder cualquier pregunta sobre nuestros productos y servicios.
Contáctenos